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Background: Previous studies have reported that artificial increases in circulating free fatty 
acid (FFA) levels might have adverse effects on the vasculature. However, whether or not this 
effect can be extrapolated to physiological variations in FFA levels has not been clarified. 
Given that FFAs exert a lipotoxic effect on pancreatic β-cells and might directly damage the 
arterial endothelium, we hypothesized that these adverse effects might synergize with 
hyperglycemia.  
Methods: A total of 9,396 Japanese subjects were included in the study. Serum FFA levels 
were measured at baseline examination. Brachial-to-ankle pulse wave velocity (baPWV) was 
measured as an index of arterial stiffness.  
Results: As serum levels of FFA were markedly lower in subjects with higher insulin level, a 
significant association between FFA levels and baPWV was observed only in subjects with 
blood samples taken under fasting (≥12 h, P<0.001) or near-fasting (5–11 h, P<0.001) 
conditions, and not in those taken under non-fasting (<5 h, P=0.307) conditions. Although 
type 2 diabetes and HbA1c showed a strong association with baPWV, the association between 
FFA level and baPWV remained significant (β=0.052, P<0.001) after adjustment for glycemic 
levels. In addition to their direct relationship, FFA and glucose levels were synergistically 
associated with baPWV (FFA*glucose; =0.036, P<0.001). Differences in baPWV between 
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the lowest and highest subgroups divided by a combination of FFA and glucose reached 
approximately 300 cm/sec. 
Conclusions: Physiological variations in FFA concentrations might be a risk factor for large 
arterial stiffness. FFA and hyperglycemia exert a synergistic adverse effect on the vasculature. 
 
HIGHLIGHTS 
l Serum free fatty acid levels are associated with large arterial stiffness. 
l The effect of serum free fatty acid levels on large arterial stiffness was increased with 
increasing glucose levels in a synergistic manner. 
l Serum free fatty acid may be a marker of cardiovascular risk. 
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Circulating free fatty acid (FFA) is released mainly by adipose tissue and is used as a major 
energy source by cardiac and skeletal muscles [1]. However, excessive FFA exposure induces 
a lipotoxic effect on pancreatic β-cells, which might reduce insulin secretion [2] and increase 
β-cell apoptosis [3]. These adverse effects of FFA were first observed in vitro and 
subsequently confirmed in vivo in both animal models [4] and human studies [5, 6], which 
reported an association of chronically high FFA levels with reduced insulin sensitivity and 
impaired compensatory increases in insulin secretion.  
In addition to lipotoxic effects on the insulin pathway that might increase the risk of 
type 2 diabetes [7], elevated circulating levels of FFA might exert a direct adverse effect on 
large arteries via impaired insulin-mediated vasodilation [8]. FFA might also exert adverse 
effects via impaired endothelium-dependent vasodilation [9]. However, nearly all human 
studies investigating the adverse effects of FFA on insulin signaling [5] and vascular function 
[8, 9] have used lipid infusion to increase circulating FFA levels. Although one small-scale 
study (n=105) [10] reported an inverse association between serum FFA levels and abdominal 
aortic distensibility, we are unaware of any data from large-scale populations on the potential 
effects of physiological variations in FFA levels on arterial properties. Longitudinal studies in 
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a general population [11] and in patients undergoing coronary angiography [12] reported 
positive associations between the elevation of FFA levels and incidence of ischemic heart 
disease, as well as cardiovascular mortality. Therefore, even physiological variations in FFA 
might result in adverse effects on arteriosclerotic vasculature change. Further, as FFA might 
exert adverse effects on arteries by bidirectional pathways [13], namely direct effects on 
vascular endothelium [14] and indirect effects via lipotoxicity, we hypothesized that higher 
circulating FFA and glucose levels have a synergistic association with arteriosclerosis. 
 Here, to further clarify the direct and synergistic adverse effects of FFA on arterial 
stiffness, we conducted a cross-sectional study by analyzing a dataset of the Nagahama 
Prospective Cohort for Comprehensive Human Bioscience (the Nagahama Study), which is a 
large-scale population-based cohort study in Japan. We also investigated factors that are 
potentially associated with circulating FFA levels to elucidate the descriptive and 




Study participants consisted of 9,396 apparently healthy middle-aged to elderly citizens who 
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were participants of the Nagahama Study. The study cohort was recruited from 2008 to 2010 
from the general population living in Nagahama City, a largely rural city of 125,000 
inhabitants located in central Japan. Residents aged 30 to 74 years living independently in the 
community and with no physical impairment or dysfunction were recruited for the Nagahama 
cohort. Of a total of 9,804 participants, those meeting any of the following conditions were 
excluded: history of cardiovascular diseases (n=266), presently taking insulin therapy (n=22), 
pregnant (n=43), or no data for or outlying clinical parameters required for this study (n=77).  
All study procedures were approved by the ethics committee of Kyoto University 
Graduate School of Medicine and the Nagahama Municipal Review Board. Written informed 
consent was obtained from all participants. 
 
Clinical characteristics of study subjects 
Basic clinical parameters, including plasma markers, were measured at baseline examination. 
Each participant was asked the time of their last meal, and fasting conditions were defined as 
follows: fasting, 12 h or more; near-fasting, 5 to 11 h; and non-fasting, less than 5 h. Serum 
FFA levels were quantified using an enzymatic assay (NEFA-HR; Wako Pure Chemical 
Industries, Ltd., Osaka, Japan). In FFA measurements, the intra-assay coefficient of variation 
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was 1.42% and inter-assay coefficient of variation was 1.79%. Smoking status and medication 
use were evaluated using a structured, self-administered questionnaire.  
 
Evaluation of arterial stiffness 
Brachial-to-ankle pulse wave velocity (baPWV) was used as an index of arterial stiffness. 
baPWV was measured by applying cuffs to both brachia and ankles, and blood pressure was 
simultaneously measured using a cuff-oscillometric device (Vasera-1500; Fukuda Denshi, 
Tokyo, Japan). Pulse volume waveforms were also simultaneously recorded using a 
plethysmographic sensor connected to the cuffs. baPWV was calculated from the time interval 
between the wave fronts of the brachial and ankle waveforms and the path length from the 
brachia to ankle (0.597 × height + 14.4014) [15]. Co-linearity of baPWV with a 
carotid-to-femoral PWV, a standard measure of arterial stiffness, has been reported [16]. 
 
Assessment of other risk factors 
Hypertension was defined as any or all of brachial systolic blood pressure (SBP) ≥140 mmHg, 
diastolic BP (DBP) ≥90 mmHg, or taking antihypertensive medication. Type 2 diabetes was 
defined as any or all of fasting plasma glucose ≥126 mg/dl, occasional plasma glucose ≥200 
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mg/dl, HbA1c ≥6.5%, and use of hypoglycemic treatment. 
 
Statistical analysis 
Group differences in numeric and categorical variables were assessed by analysis of variance 
(ANOVA) or a chi-squared test. Quartiles of numeric variables were calculated within each 
sub-group divided by fasting condition. Factors independently associated with FFA and 
baPWV were analyzed by multiple linear regression analysis. Statistical analysis was 
performed using JMP 9.0.3 software (SAS Institute, Cary, NC, USA). P-values less than 0.05 
were considered significant.  
 
RESULTS 
The structure of the Results section is schematically shown in Supplementary Figure 1. 
 
Determinants of serum FFA levels 
Clinical characteristics of subjects are summarized in Table 1. A marked sex difference in 
serum FFA level was observed, with a 20% increase in females (female=0.78±0.28, 
male=0.65±0.26 mEq/l, P<0.001). As a large proportion of serum FFA is bound to albumin, a 
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strong association was noted between serum FFA and albumin levels (r=0.188, P<0.001), but 
not with age (r=0.082) or body mass index (BMI; r=0.070).  
 Blood specimens of a substantial number of subjects were drawn under non-fasting 
conditions (Table 1). Subjects were therefore sub-divided according to fasting duration, and 
clinical characteristics were then summarized separately (Supplementary Table 1). Marked 
inter-group differences were observed in insulin and FFA levels, with the former being 
considerably higher and the latter considerably lower under non-fasting conditions. FFA and 
insulin levels showed dramatic variation depending on fasting condition (Figure 1A), and the 
pattern of variation in FFA levels was antithetical to that of insulin. Further, an inverse 
association between FFA and insulin was also observed on detailed analysis within each time 
slot (Figure 1B, Supplementary Table 2), but prolonged fasting durations diminished the 
differences in insulin levels. In contrast, no clear relationship was observed with other 
glycemic parameters, namely diabetes status or HbA1c quartile (Supplementary Table 3). 
 Smoking status was also strongly associated with serum FFA level (Supplementary 
Figure 2). Current smokers exhibited significantly lower FFA levels in both sexes, particularly 
under near-fasting and fasting conditions. 
Multivariate analysis was then performed to identify factors independently 
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associated with serum FFA levels (Supplementary Table 4). Results indicated that factors 
strongly associated with FFA level were female sex (β=0.232, P<0.001), albumin (β=0.226, 
P<0.001), and near-fasting conditions (β=0.340, P<0.001), while those inversely associated 
with FFA level were insulin (β=-0.142, P<0.001) and non-fasting conditions (β=-0.200, 
P<0.001). When multivariate analysis was performed by fasting condition, the association of 
insulin with FFA was significant only under non-fasting conditions (non-fasting, β=-0.481, 
P<0.001; near-fasting, β=-0.006, P=0.749; fasting, β=-0.036, P=0.046) (Supplementary Table 
5).  
 
FFA and arterial stiffness 
Differences in baPWV by serum FFA quartile are shown in Figure 2. In contrast to the 
relationship with insulin, FFA levels were positively associated with baPWV under 
near-fasting and fasting conditions. Consistent with previous reports, type 2 diabetes and 
impaired glycemic control were also strongly associated with baPWV in our datasets 
(Supplementary Figure 2). However, the association of FFA level with baPWV under 
near-fasting and fasting conditions remained significant (β=0.052, P<0.001) even after 
adjustment for plasma insulin or glucose level, as well as possible covariates (Models 1 and 2, 
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Table 2). Further, in addition to their direct relationship, FFA and glucose levels were 
synergistically associated with baPWV (FFA*glucose; β=0.036, P<0.001) (Model 3, Table 2). 
Subjects with higher plasma glucose levels, as well as patients with type 2 diabetes, exhibited 
larger increases in baPWV by FFA quartile than those with relatively low plasma glucose 
levels (Figure 3, Supplementary Table 6). In contrast, under non-fasting conditions, FFA and 
insulin were not identified as independent determinants for baPWV (insulin: β=0.013, 
P=0.585; FFA: β=0.030, P=0.137). 
 
DISCUSSION 
In this cross-sectional study of a large general population, we confirmed our hypothesis of an 
association between elevated serum FFA levels and large arterial stiffness [8-10] in an 
epidemiological setting. Further, the adverse effect of high FFA levels was prominent under 
poor glycemic control, particularly in patients with type 2 diabetes. Although a previous 
experimental study [17] reported a synergistic association of glucose and free fatty acid with 
lipid accumulation in macrophages, to our knowledge, this is the first large-scale report that 
physiological variation in serum FFA level might be a risk factor for large arterial stiffness, 
the effect of which increased with glucose levels in a synergistic manner. 
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Previous experimental studies demonstrated the lipotoxic effect of chronically high 
FFA levels on insulin secretion and pancreatic β-cell function [2, 3], which worsens glycemic 
control and results in insulin resistance and type 2 diabetes. In the present study, although 
both HbA1c and type 2 diabetes were factors that increased baPWV (Supplementary Figure 
2), the positive relationship between FFA and baPWV was independent of plasma levels of 
insulin and glucose (Table 2). These results support previous findings that suggest an 
insulin-independent pathophysiological pathway between FFA and large arteries, namely 
direct impairment of endothelium function [13], and might explain the mechanism by which 
elevated FFA levels synergize with glucose levels. This notion is supported by findings from a 
previous study in healthy volunteers of a concomitant decrease in systemic glucose disposal 
rate and insulin-dependent vasodilation after FFA infusion [8].  
As the adverse effects of FFA were synergistic with those of glucose in subjects 
under fasting or near-fasting conditions (Table 2), differences in baPWV between the lowest 
and highest subgroups divided by a combination of physiological variation of FFA and 
glucose reached approximately 300 cm/sec (Figure 2). Further, results of multiple regression 
analysis indicate that the correlation coefficient of FFA for baPWV is equivalent to that of 
glucose (Table 2). More attention should therefore be paid to FFA as a cardiovascular risk 
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factor in epidemiological studies among general populations, as well as in clinical settings. 
Serum FFA levels were lowest under non-fasting conditions, whereas insulin levels 
were highest under these conditions (Figure 1). The relatively low levels of FFA under fasting 
conditions might therefore be explained by decreases in insulin-mediated FFA secretion from 
adipose tissue and increases in FFA uptake in the liver and muscle. Similar patterns of change 
in FFA and insulin levels were observed after intravenous infusion of glucose [18, 19]. As 
delayed exogenous insulin infusion did not affect these patterns [19], the initial endogenous 
secretion of insulin might be an important determinant of FFA level after glucose load. FFA 
levels are thus primarily influenced by insulin levels and as such, the use of FFA as a 
cardiovascular risk factor should be done with careful consideration to the involvement of 
confounding factors that may alter insulin levels, such as dietary intake and insulin therapy. 
Given that FFA levels were lower in current smokers (Supplementary Figure 2), smoking 
status should be considered as another confounding factor. A previous interventional study in 
heavy smokers [20] reported acute increases in FFA levels 3 h after smoking. The chronic and 
acute effects of smoking on serum FFA levels might differ. In addition, marked circadian 




In a sub-analysis of the 10 time slots shown in Figure 1B, insulin levels were lower 
in subjects with higher FFA quartiles. This inverse association remained significant after 
adjustment for glucose level, possibly demonstrating the lipotoxic effect of FFA. Given that 
the inverse association between FFA and insulin disappeared under fasting conditions, the 
lipotoxic effect of FFA against pancreatic β-cells mainly impaired additional insulin secretion 
after glycemic load. 
Several limitations to the present study warrant mention. First, repeated measure of 
FFA levels was not available. Although some day-to-day variation in FFA levels may exist, 
we did not consider intra-individual variation in the present study. Second, as this was an 
observational study, the fasting duration-related changes in FFA and insulin levels were 
compared by sub-population and not by time-dependent analysis. However, as our study had a 
large sample size, individual differences between each subgroup might be negligible when 
evaluating the pattern of changes in FFA and insulin. Third, we did not measure the 
composition of FFA. Eguchi et al. reported that palmitic acid might play a key role in β cell 
dysfunction and islet inflammation [22]. Detailed analysis based on fatty acid composition 
might provide further insight into the adverse effects of FFA. Fourth, our study was conducted 
under a cross-sectional design, and longitudinal investigations are required to clarify the 
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prognostic significance of FFA on cardiovascular outcomes. A limited number of longitudinal 
studies in patients with myocardial infarction [23] and those scheduled for coronary 
angiography [24] have suggested a positive relationship between elevated FFA and 
cardiovascular and all-cause mortality.    
In conclusion, physiological variation in FFA levels might increase the risk of large 
arterial stiffness in a general population, and the pathophysiological pathway might be 
independent of FFA lipotoxicity. As insulin affects serum FFA levels, factors that potentially 
confound circulating insulin levels should be carefully considered when evaluating the 
adverse effects of FFA.  
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Figure 1. Association between serum FFA and insulin levels by fasting status 
A: Fasting time-related changes in free fatty acid (FFA) and insulin levels. B: Differences in 
insulin levels by quartile of FFA and fasting time. Subjects were divided into quartiles within 
each subgroup. Significance was assessed by analysis of covariance. Detailed data are shown 
in Supplementary Table 2. 
 
Figure 2. Association of FFA quartile with arterial stiffness 
Fasting condition at blood sampling was defined as follows: ≥12 h, fasting; 5–11 h, 
near-fasting; and <5 h, non-fasting. Quartiles of free fatty acid (FFA) levels were calculated 
within subgroups. Differences in brachial-to-ankle pulse wave velocity (baPWV) were 
assessed by analysis of variance. Numbers of subjects in each subgroup are shown in 
columns. 
 
Figure 3. Synergistic association of FFA and glycemic level with arterial stiffness in 
subjects under fasting or near-fasting conditions (n=8,059) 
Quartiles of free fatty acid (FFA) were calculated within subgroups stratified by fasting 
condition (fasting and near-fasting) and then combined. Type 2 diabetes (T2DM) was defined 
as any or all of fasting plasma glucose ≥126 mg/dl, occasional plasma glucose ≥200 mg/dl, 
glycosylated hemoglobin A1c ≥6.5%, and use of hypoglycemic treatment. Remaining subjects 
who did not receive hypoglycemic medication were subdivided by plasma glucose level. 




Table 1. Clinical characteristics of subjects (n=9,396) 
Age (years) 53±13 
Sex (male %) 32.3 
BMI (kg/m2) 22.3±3.3 
Current smoking (%) 14.5 
Fasting condition (fasting/near-fasting/non-fasting) 4,324/3,735/1,337 
Blood pressure  
 SBP (mmHg) 123±18 
 DBP (mmHg) 76±11 
 Antihypertensive medication (%) 15.9 
 Hypertension (%) 29.7 
Metabolic parameters  
 Glucose (mg/dl) 90±14 
 Insulin (µU/ml) 5.37±4.95 
 HbA1c (%) 5.5±0.5 
 Hypoglycemic medication (%) 2.4 
 Type 2 diabetes (%) 3.7 
 Total cholesterol (mg/dl) 207±35 
 HDL cholesterol (mg/dl) 65±17 
 LDL cholesterol (mg/dl) 123±31 
 Triglyceride (mg/dl) 98±66 
 Albumin (g/dl) 4.48±0.23 
 FFA (mEq/l) 0.74±0.28 
hsCRP (µg/ml) 0.88±3.40 
baPWV (cm/sec) 1,261±228 
BMI, body mass index; HbA1c, glycosylated hemoglobin A1c; FFA, free fatty acid; hsCRP, 
high sensitive C-reactive protein; baPWV, brachial-to-ankle pulse wave velocity 
Fasting condition at blood sampling was defined as follows: fasting, ≥12 h; near-fasting, 5–
11 h; and non-fasting, <5 h. Hypertension was defined as any or all of brachial systolic blood 
pressure (SBP) ≥140 mmHg, diastolic BP (DBP) ≥90 mmHg, or use of antihypertensive 
medication. Type 2 diabetes was defined as any or all of fasting plasma glucose ≥126 mg/dl, 
occasional plasma glucose ≥200 mg/dl, HbA1c ≥6.5%, and use of hypoglycemic treatment. 
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Table 2. Multiple linear regression analysis for arterial stiffness in subjects under fasting or near-fasting conditions (n=8,059) 
 baPWV (cm/sec) 
 Model 1 Model 2 Model 3 
 β P β P β P 
Age (years) 0.426 <0.001 0.414 <0.001 0.413 <0.001 
Sex (male) 0.019 0.028 0.012 0.154 0.014 0.101 
BMI (kg/m2) −0.093 <0.001 −0.088 <0.001 −0.088 <0.001 
Current smoking <0.001 0.986 0.001 0.912 <0.001 0.963 
SBP (mmHg) 0.389 <0.001 0.384 <0.001 0.383 <0.001 
Antihypertensive medication 0.108 <0.001 0.108 <0.001 0.107 <0.001 
Albumin (g/dl) 0.037 <0.001 0.035 <0.001 0.034 <0.001 
HDL cholesterol (mg/dl) −0.024 0.006 −0.026 0.003 −0.027 0.002 
LDL cholesterol (mg/dl) 0.008 0.309 0.007 0.353 0.007 0.378 
Triglyceride (mg/dl) 0.011 0.183 0.009 0.275 0.009 0.313 
Glucose (mg/dl)   0.063 <0.001 0.066 <0.001 
Antihyperglycemic treatment 0.047 <0.001 0.030 <0.001 0.032 <0.001 
Insulin (log-normalized) 0.059 <0.001 0.043 <0.001 0.043 <0.001 
hsCRP (log-normalized) 0.071 <0.001 0.067 <0.001 0.067 <0.001 
FFA (mEq/l) 0.051 <0.001 0.052 <0.001 0.054 <0.001 
Glucose*FFA interaction     0.036 <0.001 
baPWV, brachial-to-ankle pulse wave velocity; BMI, body mass index; SBP, systolic blood pressure; hsCRP, high-sensitive C-reactive protein; 
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Supplementary Table 1. Clinical characteristics of study subjects by fasting condition 





Age (years old) 52±14 54±13 53±13 <0.001 
Sex (male %) 32.8 32.9 31.6 0.419 
BMI (kg/m2) 22.3±3.3 22.4±3.3 22.1±3.2 0.005 
Current smoking (%) 20.2 13 14.1 <0.001 
Blood pressure     
 SBP (mmHg) 122±18 124±18 123±18 <0.001 
 DBP (mmHg) 75±11 76±11 76±11 <0.001 
 Antihypertensive treatment (%) 14.5 16.7 15.6 0.169 
 Hypertension (%) 26.8 31.1 29.5 0.011 
Metabolic parameters     
 Glucose (mg/dl) 92±20 89±11 90±14 <0.001 
 Insulin (µU/ml) 8.51±9.63 4.63±3.63 5.03±3.08 <0.001 
 HbA1c (%) 5.4±0.5 5.5±0.5 5.5±0.5 0.029 
 Antihyperglycemic treatment (%) 2.2 2.5 2.4 0.803 
 Type 2 diabetes (%) 3 3.7 4 0.251 
 Total cholesterol (mg/dl) 203±34 208±35 207±34 <0.001 
 HDL cholesterol (mg/dl) 64±17 66±17 66±17 0.001 
 LDL cholesterol (mg/dl) 120±30 124±32 123±31 <0.001 
 Triglyceride (mg/dl) 111±72 100±69 91±62 <0.001 
 Albumin (g/dl) 4.46±0.24 4.49±0.22 4.47±0.22 <0.001 
 FFA (mEq/l) 0.61±0.32 0.84±0.29 0.69±0.24 <0.001 
hsCRP (µg/ml) 0.88±4.01 0.90±3.32 0.86±3.26 0.832 
baPWV (cm/sec) 1,239±220 1,270±229 1,261±231 <0.001 
BMI, body mass index; HbA1c, glycosylated hemoglobin A1c; FFA, free fatty acid; hsCRP, 
high sensitive C-reactive protein; baPWV, brachial-to-ankle pulse wave velocity. 
Fasting condition at blood sampling was defined as follows; fasting, ≥12 h; near-fasting, 5 to 
11 h; non-fasting, <5 h. Hypertension was defined as any or all of brachial systolic blood 
pressure (SBP) ≥140 mmHg, diastolic BP (DBP) ≥90 mmHg, or taking antihypertensive 
medication. Type 2 diabetes was defined as any or all of fasting plasma glucose ≥126 mg/dl, 
occasional plasma glucose ≥200 mg/dl, HbA1c ≥6.5 %, and use of hypoglycemic treatment.  
 
Supplementary Table 2. Insulin levels classified by fasting duration and FFA quartile 
   Fasting duration (hours) 
 
  
<1 <2 <3 <4 <5 <6 <7 <9 <11 ≥12 
Total  n 122 220 427 568 865 1245 987 450 188 4,324 
  mean 15.44 13.37 7.30 6.04 4.86 4.64 4.38 4.38 5.48 5.03 
  (SD) (13.91) (12.95) (7.58) (6.54) (3.95) (3.90) (3.07) (2.85) (4.42) (3.08) 
             
FFA quartile Q1 n 29 49 103 132 211 302 234 111 46 1,047 
 
 
mean 22.44 19.59 13.55 11.07 6.23 5.61 4.67 4.83 4.83 5.19 
 
 
(SD) (13.23) (15.30) (10.93) (10.58) (6.15) (6.32) (4.19) (3.44) (3.69) (3.21) 
             
 Q2 n 31 61 108 152 212 313 249 114 44 1,062 
 
 
mean 23.87 17.48 6.52 5.22 4.70 4.21 4.32 3.76 5.53 5.05 
 
 
(SD) (17.42) (12.91) (6.61) (4.68) (3.11) (2.51) (2.74) (2.20) (4.56) (3.12) 
             
 Q3 n 32 55 109 136 218 307 252 111 46 1,111 
 
 
mean 9.46 11.66 4.69 4.10 4.33 4.18 4.25 4.58 6.33 4.97 
 
 
(SD) (6.64) (11.90) (3.35) (2.64) (2.90) (2.81) (2.49) (3.03) (5.60) (2.91) 
             
 Q4 n 30 55 107 148 224 323 252 114 52 1,104 
 
 
mean 6.33 4.97 4.72 4.17 4.22 4.57 4.32 4.37 5.27 4.92 
 
 
(SD) (5.16) (4.08) (2.85) (2.41) (2.24) (2.55) (2.61) (2.49) (3.66) (3.07) 
FFA, free fatty acids. 
Unit of insulin is µU/ml. Quartile of FFA was calculated within each timeslot.  
Supplementary Table 3. Association of FFA with glycemic parameters 
   FFA (mEq/l)  
  Non-fasting (<5 h) Near-fasting (5 to 11 h) Fasting (≥12 h) 
  N Mean±SD P N Mean±SD P N Mean±SD P 
Insulin quartile Q1 331 0.72±0.25 <0.001 927 0.83±0.26 <0.001 1081 0.69±0.25 0.215 
 Q2 336 0.73±0.31  935 0.86±0.29  1081 0.69±0.24  
 Q3 336 0.63±0.32  939 0.87±0.28  1081 0.70±0.24  
 Q4 334 0.36±0.22  934 0.81±0.31  1081 0.68±0.24  
           
Type 2 diabetes T2DM 40 0.54±0.33 0.156 139 0.78±0.29 0.008 172 0.71±0.22 0.385 
 NGT 1297 0.61±0.32  3596 0.84±0.28  4152 0.69±0.24  
           
Antihyperglycemic 
treatment 
Yes 29 0.50±0.33 0.063 93 0.75±0.28 0.001 103 0.68±0.21 0.597 
No 1,308 0.61±0.32  3,642 0.84±0.28  4,221 0.69±0.24  
           
HbA1c quartile Q1 404 0.63±0.32 0.164 987 0.84±0.31 0.817 1145 0.69±0.26 0.244 
 Q2 351 0.60±0.31  950 0.84±0.28  1120 0.68±0.24  
 Q3 267 0.61±0.33  1094 0.84±0.28  1295 0.69±0.23  
 Q4 315 0.58±0.31  704 0.83±0.27  764 0.71±0.22  
FFA, free fatty acids; T2DM, type 2 diabetes; NGT, normal glycemic tolerance; HbA1c, glycosylated hemoglobin A1c 
Values are mean ± standard deviation. Type 2 diabetes was defined as any or all of fasting plasma glucose ≥126 mg/dl, occasional plasma glucose 
≥200 mg/dl, HbA1c ≥6.5%, and use of hypoglycemic treatment. Quartiles of insulin and HbA1c were calculated within each subgroup. Statistical 
significance was assessed by analysis of variance. 
Supplementary Table 4. Multiple linear regression analysis for serum FFA level (n=9.396) 
 FFA (mEq/l) 
 β P 
Age (years old) 0.100 <0.001 
Sex (male) -0.232 <0.001 
BMI (kg/m2) 0.025 0.034 
Current smoking -0.036 <0.001 
SBP (mmHg) 0.062 <0.001 
Antihypertensive treatment 0.013 0.212 
Albumin (g/dl) 0.226 <0.001 
HDL cholesterol (mg/dl) 0.112 <0.001 
LDL cholesterol (mg/dl) -0.001 0.952 
Triglyceride (mg/dl) 0.016 0.133 
Glucose (mg/dl) -0.012 0.246 
Antihyperglycemic treatment -0.010 0.301 
Insulin (log-normalized) -0.142 <0.001 
hsCRP (log-normalized) 0.072 <0.001 
Fasting condition Fasting (≥12 h) reference 
 Near-fasting (5 to 11 h) 0.340 <0.001 
 Non-fasting (<5 h) -0.200 <0.001 
FFA, free fatty acid; BMI, body mass index; SBP, systolic blood pressure; hsCRP, high 
sensitive C-reactive protein; baPWV, brachial-to-ankle pulse wave velocity.  
Fasting condition at blood sampling was defined as follows; fasting, ≥12 h; near-fasting, 5 to 
11 h; non-fasting, <5 h. 
 
Supplementary Table 5. Multiple linear regression analysis for serum FFA level by fasting status 
 FFA (mEq/l) 
 
Non-fasting (<5 h) Near-fasting (5 to 11 h) Fasting (≥12 h) 
 
β P β P β P 
Age (years old) -0.004 0.882 0.160 <0.001 0.115 <0.001 
Sex (male) -0.221 <0.001 -0.227 <0.001 -0.238 <0.001 
BMI (kg/m2) 0.134 <0.001 -0.024 0.236 -0.040 0.033 
Current smoking -0.014 0.577 -0.040 0.014 -0.053 0.001 
SBP (mmHg) 0.032 0.236 0.072 <0.001 0.055 0.002 
Antihypertensive treatment 0.049 0.050 -0.009 0.602 0.021 0.193 
Albumin (g/dl) 0.227 <0.001 0.218 <0.001 0.209 <0.001 
HDL cholesterol (mg/dl) 0.077 0.005 0.135 <0.001 0.134 <0.001 
LDL cholesterol (mg/dl) 0.082 0.001 -0.006 0.697 -0.036 0.020 
Triglyceride (mg/dl) 0.007 0.812 -0.006 0.732 0.048 0.005 
Glucose (mg/dl) 0.017 0.571 -0.031 0.068 0.024 0.158 
Antihyperglycemic treatment 0.005 0.852 -0.030 0.061 -0.007 0.639 
Insulin (log-normalized) -0.481 <0.001 -0.006 0.749 -0.036 0.046 
hsCRP (log-normalized) 0.058 0.020 0.049 0.005 0.096 <0.001 
baPWV, brachial-to-ankle pulse wave velocity; BMI, body mass index; SBP, systolic blood pressure; hsCRP, high-sensitive C-reactive protein; 
FFA, free fatty acid.  
Fasting condition at blood sampling was defined as follows; fasting, ≥12 h; near-fasting, 5 to 11 h; non-fasting, <5 h. 
Supplementary Table 6. Mean baPWV by FFA quartile and glycemic control level in subjects under fasting or near-fasting condition (n=8,059) 
  FFA quartile 
 
 
Q1 Q2 Q3 Q4 
  n Mean±SD n Mean±SD n Mean±SD n Mean±SD 
Glucose (mg/dl) <90 1167 1178±183 1147 1211±227 1236 1219±206 1145 1223±211 
 ≥90 550 1238±197 577 1287±200 629 1335±227 629 1369±263 
 ≥100 153 1351±212 154 1391±239 163 1420±195 198 1460±249 
T2DM 
 
89 1474±237 75 1450±203 75 1460±191 72 1525±233 
FFA, free fatty acid; T2DM, type 2 diabetes. 
Values are mean ± standard deviation. FFA quartile was calculated within subgroups stratified by fasting condition (fasting and near-fasting) and 
then combined. T2DM was defined as any or all of fasting plasma glucose ≥126 mg/dl, occasional plasma glucose ≥200 mg/dl, glycosylated 
hemoglobin A1c ≥6.5 %, and use of hypoglycemic treatment. Remaining subjects who did not receive hypoglycemic medication were subdivided 
by plasma glucose level.  
  
































Supplementary Figure 2. Smoking status and serum FFA levels. 
Number of subjects in each sub-group are shown in parentheses. Statistical significance was 
assessed by analysis of variance.  
Fasting condition at blood sampling was defined as follows; fasting, ≥12 h; near-fasting, 5 to 




















































































































Total Non-fasting Near-fasting Fasting
P<0.001 P=0.382 P=0.119 P<0.001
P<0.001 P=0.311 P<0.001 P<0.001
(178) (160) (101) (353) (543) (332) (422) (618) (326)








Supplementary Figure 3.  Effect of glycemic control on arterial stiffness. 
baPWV, brachial-to-ankle pulse wave velocity; T2DM, type 2 diabetes; HbA1c, glycosylated 
hemoglobin A1c.  
Type 2 diabetes was defined as any or all of fasting plasma glucose ≥126 mg/dl, occasional 
plasma glucose ≥200 mg/dl, HbA1c ≥6.5 %, and use of hypoglycemic treatment. Quartile of 
HbA1c was calculated within subgroups stratified by fasting condition (non-fasting, 
near-fasting, fasting) and then combined. Statistical significance was assessed by analysis of 
variance. Number of subjects in each subgroup are shown in column. 
 
 
Q1 Q2 Q3 Q4
HbA1c quartile
1100
1200
1300
1400
1500
1600
NGT T2DM
ba
PW
V 
(c
m
/s
ec
)
Diabetes
A B
9,
04
5
35
1
2,
53
6
2,
42
1
2,
65
6
1,
78
3
F = 352.4
P < 0.001
F = 312.3
P < 0.001
